LCM
IKT icon

Lynx1 Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Lynx1 Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.6K Buy
+20,000
New +$35.8K ﹤0.01% 27

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Lynx1 Capital Management's IKT Position: Q2 2026 in Review

Lynx1 Capital Management opened a new position in Inhibikase Therapeutics (IKT) in Q2 2026: 20,000 shares worth $40.6K. The stake represents ﹤0.01% of the portfolio and ranks #27 among its holdings.

106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Lynx1 Capital Management held 20,000 shares of Inhibikase Therapeutics worth $40.6K as of Q2 2026.
  • Inhibikase Therapeutics was a new Lynx1 Capital Management position in Q2 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Lynx1 Capital Management's portfolio in Q2 2026, its #27 holding.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.